| Autor: |
Bialkower M; BioPRIA and Department of Chemical Engineering, Monash University, Clayton, Australia., Garnier G; BioPRIA and Department of Chemical Engineering, Monash University, Clayton, Australia. |
| Jazyk: |
angličtina |
| Zdroj: |
Critical reviews in analytical chemistry [Crit Rev Anal Chem] 2022; Vol. 52 (1), pp. 194-209. Date of Electronic Publication: 2020 Jul 20. |
| DOI: |
10.1080/10408347.2020.1793098 |
| Abstrakt: |
Fibrinogen is one of the first factors to fall to critically low levels in the blood in many coagulopathic events. Patients with hypofibrinogenemia are at a significantly greater risk of major hemorrhage and death. The rapid replacement of fibrinogen early on in hypofibrinogenemia may significantly improve outcomes for patients. Fibrinogen is present at concentrations between 2 and 4 g/L in the plasma of healthy people. However, hypofibrinogenemia is diagnosed when the fibrinogen level drops below 1.5-2 g/L. This review analyses different types of fibrinogen assays that can be used for diagnosing hypofibrinogenemia. The scientific mechanisms and limitations behind these tests are then presented. Additionally, the current state of clinical major hemorrhage protocols (MHPs) is presented and the structure, function and physiological role of fibrinogen is summarized. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
